Immunomedics, Inc. (NASDAQ:IMMU)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

IMMU News and Commentary

Caps

How do you think IMMU will perform against the market?

Add Stock to CAPS Watchlist

All Players

212 Outperform
20 Underperform
 

All-Star Players

24 Outperform
3 Underperform
 

Wall Street

7 Outperform
1 Underperform
 

Top IMMU Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

NeroSagetrade (91.69)
Submitted October 13, 2007

This is my one...my ONE feel good story in my CAPS portfolio. I've followed Immunomedics for roughly six years and I've liked the direction management has taken the company in each successive year. They have never tried to mislead investors or the… More

zzlangerhans (99.80)
Submitted November 24, 2016

Surprisingly, my recent long bet on Immunomedics turned out to be a winner. Perhaps I have Trump to thank for that since I bought in shortly before the election surprise. Or perhaps I just got lucky: I've made a dozen bottom feeding picks in the last… More

IMMU VS S&P 500 (SPY)

Fools bullish on IMMU are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about IMMU.

Recs

2
Member Avatar zzlangerhans (99.80) Submitted: 11/24/2016 5:24:20 PM : Underperform Start Price: $3.53 IMMU Score: -128.75

Surprisingly, my recent long bet on Immunomedics turned out to be a winner. Perhaps I have Trump to thank for that since I bought in shortly before the election surprise. Or perhaps I just got lucky: I've made a dozen bottom feeding picks in the last couple of months and not of all them can plunge straight down, I suppose. My bull thesis on Immunomedics was that the stock would rocket upward once the company initiated the phase III trial of sacituzumab for triple negative breast cancer and simultaneously filed for accelerated approval. I hoped this would happen around the end of 2016. Instead, Immunomedics recently announced that they wouldn't be initiating the trial until mid 2017, which I anticipate eventually will be narrowed down to Q3 2017 and then more than likely postponed to Q4 2017. Even if they remain on the current schedule, there's a strong likelihood of another below market dilutive financing with warrants before any positive catalyst. The last financing crushed the stock well below the offering price. Another bearish factor is that the share price is approaching the warrant exercise price of 3.75, which could lead to further dilution. I wouldn't short Immunomedics yet, but I was glad to liquidate my long position for a healthy profit and I'll be watching any rise over the warrant exercise price with great interest.

Recs

0
Member Avatar Hendrickson71 (< 20) Submitted: 10/28/2015 3:54:26 PM : Underperform Start Price: $2.87 IMMU Score: -177.22

That was a tough month. Done, out no profit, no loss. Thanks for nothing.

Recs

0
Member Avatar a410traveler (60.38) Submitted: 4/23/2015 11:37:31 AM : Outperform Start Price: $4.12 IMMU Score: +89.11

Strong pipeline of drugs

Leaderboard

Find the members with the highest scoring picks in IMMU.

Score Leader

GyroDynasty

GyroDynasty (97.91) Score: +420.79

The Score Leader is the player with the highest score across all their picks in IMMU.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
GyroDynasty 97.91 9/29/2015 Outperform 5Y $1.57 +436.31% +28.92% +407.39 0 Comment
wmtworker 70.32 8/3/2015 Outperform 5Y $2.05 +310.73% +15.32% +295.41 0 Comment
bibbes < 20 8/3/2015 Outperform 5Y $2.05 +310.73% +15.32% +295.41 0 Comment
pavlos1971 99.06 8/3/2015 Outperform 5Y $2.05 +310.73% +15.32% +295.41 0 Comment
beemer330 74.55 7/14/2016 Outperform 1Y $2.21 +281.00% +12.25% +268.74 0 Comment
lgrunner34 26.17 10/18/2016 Outperform 5Y $2.23 +277.58% +13.36% +264.22 0 Comment
DGGO999 23.81 11/26/2007 Outperform 1Y $2.07 +306.76% +76.07% +230.70 0 Comment
mikolabruce 21.69 10/10/2006 Outperform 3M $2.00 +321.00% +90.67% +230.33 0 Comment
Exampleman35 < 20 9/17/2007 Outperform 3M $2.17 +288.02% +72.32% +215.70 1 Comment
JoeCasino < 20 10/6/2016 Outperform 5Y $2.60 +223.85% +12.69% +211.15 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
trackchardan 26.46 1/8/2014 Outperform NS $5.02 +67.73% +32.30% +35.43 0 Comment
TrackJimCramer 84.81 8/15/2013 Underperform 3W $5.11 +64.77% +45.88% -18.90 0 Comment
TrackUltraLong 24.45 1/23/2013 Outperform NS $2.91 +189.35% +62.75% +126.60 1 Comment
tracksummerstree 91.29 8/31/2011 Outperform NS $4.00 +110.50% +98.20% +12.30 0 Comment
TrackOppenheimer 64.36 5/17/2011 Outperform NS $3.77 +123.34% +82.92% +40.43 0 Comment
TrackWedbush 84.65 2/23/2011 Outperform NS $3.36 +150.60% +85.29% +65.31 0 Comment
TrackJGreenblatt 64.64 2/16/2010 Outperform 1Y $3.05 +21.31% +22.15% -0.84 2/28/2011 @ $3.70 1 Comment
TrackBreanMurray 77.82 7/3/2007 Outperform NS $4.32 +94.91% +67.89% +27.02 0 Comment
TrackLazardCapit 79.00 2/20/2007 Outperform NS $4.76 +76.89% +77.19% -0.30 0 Comment

Featured Broker Partners